US2007184530A1PendingUtilityA1

Long-acting veterinary polypeptides and methods of producing and administering same

63
Assignee: FARES FUADPriority: Feb 3, 2006Filed: Feb 5, 2007Published: Aug 9, 2007
Est. expiryFeb 3, 2026(expired)· nominal 20-yr term from priority
Inventors:Fuad FaresUdi Eyal Fima
A61P 43/00A61P 7/06A61P 5/06A61P 7/00A61P 3/04A61P 3/00A61P 35/00A61P 31/12A61K 38/27A61K 38/19C07K 2319/00C07K 14/61C07K 14/52C07K 19/00C07K 2319/31C07K 14/59C07K 14/555C07K 14/505A61K 38/00A61K 38/1816A61K 38/24A61K 38/20C07K 14/575
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.

Claims

exact text as granted — not AI-modified
1 . A polypeptide comprising a non-human peptide of interest and at least two chorionic gonadotrophin carboxy terminal peptides, wherein a first chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to an amino terminus of said non-human peptide of interest, and a second chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to a carboxy terminus of said non-human peptide of interest.  
     
     
         2 . The polypeptide of  claim 1 , wherein the sequence of at least 1 of said at least two chorionic gonadotrophin carboxy terminal peptides comprises an amino acid sequence selected from sequences set forth in SEQ ID NO: 17 and SEQ ID NO: 18.  
     
     
         3 . The polypeptide of  claim 1 , wherein at least 1 of said at least two chorionic gonadotrophin carboxy terminal peptides is truncated.  
     
     
         4 . The polypeptide of  claim 1 , wherein said non-human peptide of interest is a GH peptide.  
     
     
         5 . The polypeptide of  claim 1 , wherein said non-human peptide of interest is an EPO peptide.  
     
     
         6 . The polypeptide of  claim 1 , wherein said non-human peptide of interest is selected from an interferon peptide and a GLP-1 peptide.  
     
     
         7 . The polypeptide of  claim 1 , wherein said non-human peptide of interest is glycosylated.  
     
     
         8 . The polypeptide of  claim 1 , wherein said non-human peptide of interest is non-glycosylated.  
     
     
         9 . The polypeptide of  claim 1 , wherein at least 1 of said at least two chorionic gonadotrophin carboxy terminal peptides is glycosylated.  
     
     
         10 . The polypeptide of  claim 1 , wherein at least 1 of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to said non-human peptide of interest via a linker.  
     
     
         11 . The polypeptide of  claim 10 , wherein said linker is a peptide bond.  
     
     
         12 . The polypeptide of  claim 1 , further comprising a signal peptide.  
     
     
         13 . The polypeptide of  claim 12 , wherein said signal peptide is as set forth in SEQ ID NO: 19.  
     
     
         14 . The polypeptide of  claim 1 , wherein said polypeptide further comprises a third chorionic gonadotrophin carboxy terminal peptide attached in tandem to said second chorionic gonadotrophin carboxy terminal peptide.  
     
     
         15 . A polynucleotide comprising a coding portion encoding a polypeptide, said polypeptide comprising a non-human peptide of interest and at least two chorionic gonadotrophin carboxy terminal peptides, wherein a first chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to an amino terminus of said non-human peptide of interest, and a second chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to the carboxy terminus of said non-human peptide of interest.  
     
     
         16 . The polynucleotide of  claim 15 , wherein said polypeptide further comprises a third chorionic gonadotrophin carboxy terminal peptide attached in tandem to said second chorionic gonadotrophin carboxy terminal peptide.  
     
     
         17 . The polynucleotide of  claim 15 , wherein said non-human peptide of interest is a GH peptide.  
     
     
         18 . The polynucleotide of  claim 15 , wherein said non-human peptide of interest is an EPO peptide.  
     
     
         19 . The polynucleotide of  claim 15 , wherein said non-human peptide of interest is selected from an interferon peptide and a GLP-1 peptide.  
     
     
         20 . The polynucleotide of  claim 15 , wherein said non-human polypeptide further comprises a signal peptide.  
     
     
         21 . The polynucleotide of  claim 20 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.  
     
     
         22 . A cell comprising the expression vector of  claim 22 .  
     
     
         23 . A veterinary pharmaceutical composition comprising the expression vector of  claim 22 .  
     
     
         24 . A method of treating or reducing the incidence associated with a growth, weight-related, or metabolic condition in a non-human subject, said method comprising administering to said subject a therapeutically effective amount of a polypeptide, said polypeptide comprising: 
 (a) a peptide of interest and (b) at least two chorionic gonadotrophin carboxy terminal peptides, wherein:    a first chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to an amino terminus of said peptide of interest, and a second chorionic gonadotrophin carboxy terminal peptide of said at least two chorionic gonadotrophin carboxy terminal peptides is attached to the carboxy terminus of said peptide of interest,    thereby treating said non-human subject having a growth, weight-related, or metabolic condition.    
     
     
         25 . A method of administering a peptide of interest to a non-human subject in need thereof, comprising the step of attaching a first chorionic gonadotrophin carboxy terminal peptide to an amino terminus of said peptide of interest and a second chorionic gonadotrophin carboxy terminal peptide to the carboxy terminus of said peptide of interest, thereby generating an improved polypeptide for administration to said subject, thereby administering a peptide of interest to a subject in need thereof.  
     
     
         26 . The method of  claim 25 , further comprising the step of attaching a third chorionic gonadotrophin carboxy terminal peptide in tandem to said second chorionic gonadotrophin carboxy terminal peptide.  
     
     
         27 . The method of  claim 25 , wherein the sequence of at least one of said chorionic gonadotrophin carboxy terminal peptides comprises an amino acid sequence selected from the sequences as set forth in SEQ ID NO: 17-18.  
     
     
         28 . The method of  claim 25 , wherein said peptide of interest is a GH peptide.  
     
     
         29 . The method of  claim 25 , wherein said peptide of interest is an EPO peptide.  
     
     
         30 . The method of  claim 25 , wherein said peptide of interest is selected from an interferon peptide and a GLP-1 peptide.  
     
     
         31 . The method of  claim 25 , wherein said peptide of interest is glycosylated.  
     
     
         32 . The method of  claim 25 , wherein said improved polypeptide further comprises a signal peptide.  
     
     
         33 . The method of  claim 32 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

Join the waitlist — get patent alerts

Track US2007184530A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.